Christophe Weber, Takeda CEO (Kyodo via AP Images)
Takeda fleshes out CNS pact with peptide drugmaker, setting aside $3.5B in future milestones
One of a suite of drugmakers looking to reinvest in the neuroscience space, Takeda has been aggressive in signing on new partners to help build …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
